Syndax Pharmaceuticals Inc Stock News

WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call Transcript

Wall Street brokerages predict that Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) will announce earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Syndax Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.63) and the lowest estimate coming in at ($0.65). Syndax Pharmaceuticals reported []

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's

The stock price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) increased by over 14% today. This is why it happened.

WALTHAM, Mass., Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipel

WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call Transcript

Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

WALTHAM, Mass., June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipelin